Objective: To investigate whether vitamin B 6 supplementation had a beneficial effect on lowering fasting plasma homocysteine concentrations in coronary artery disease (CAD) patients. Design: A single-blind intervention study. Setting: The study was performed at the Taichung Veterans General Hospital, the central part of Taiwan. Subjects: A total of 50 subjects were identified by cardiac catheterization to have at least 70% stenosis of one major coronary artery. In all, 42 patients successfully completed this study. Interventions: Patients were randomly assigned to one of five groups and treated with a daily dose of placebo (n ¼ 8), 5 mg vitamin B 6 (n ¼ 8), 10 mg vitamin B 6 (n ¼ 8), 50 mg vitamin B 6 (n ¼ 9), or 5 mg folic acid combined with 0.25 mg vitamin B 12 (n ¼ 9) for 12 weeks. Main outcome measures: Nutrient intakes were recorded by using 24-h diet recalls when patients returned to the cardiology clinic before the intervention (week 0) and at week 12. Vitamin B 6 status was assessed by direct measures (plasma pyridoxal 5 0 -phosphate) and indirect measures (erythrocyte alanine and aspartate aminotransaminase activity coefficient). Fasting plasma homocysteine, serum folic acid, and vitamin B 12 were measured. Results: Fasting plasma homocysteine concentration did not respond to high or low doses of vitamin B 6 when compared with a placebo treatment after 12 weeks of supplementation. The mean fasting plasma homocysteine concentration, however, decreased significantly after 12 weeks of folic acid combined with vitamin B 12 supplementation (P ¼ 0.047). Further, within group, mean fasting plasma homocysteine concentration was nonsignificantly increased by 25.5, 16.2, and 18.3% in placebo, 10 mg/day and 50 mg/day vitamin B 6 supplemented groups, respectively; whereas folic acid combined with vitamin B 12 supplementation significantly reduced fasting plasma homocysteine concentration by 32% (Po0.001). Conclusions: Our results indicate that vitamin B 6 supplementation alone is less effective than folic acid combined with vitamin B 12 in lowering plasma homocysteine concentrations in CAD patients.
Introduction
Studies have shown that hyperhomocysteinemia is an independent risk factor for coronary artery disease (CAD) (Stampfer et al, 1992; Boushey et al, 1995; Bautista et al, 2002; Ford et al, 2002; Rydlewicz et al, 2002) . Many factors are associated with elevated homocysteine concentration. Of the most interest are nutritional deficiencies in the vitamin cofactors that are required for homocysteine metabolism; namely folic acid, vitamins B 12 and B 6 . Most cross-sectional, retrospective, case-controlled, and prospective cohort studies (Lindenbaum et al, 1990; Boushey et al, 1995; Morrison et al, 1996; Verhoef et al, 1996; Bailey et al, 2002) have shown that folic acid and vitamin B 12 intake and/or biochemical status have a strong negative correlation with fasting plasma homocysteine concentration. A recent meta-analysis indicated that dietary supplementation in the range of 0.5-5 mg/ day folic acid reduced homocysteine concentrations by 25% (95% CI: 23-28%); mean 0.5 mg/day vitamin B 12 intake produced an additional 7% (95% CI: 3-10%) reduction in homocysteine levels (Clarke & Armitage, 2000) . Thus, it is suggested that folic acid combined with vitamin B 12 supplementation may be protective via lowering of fasting plasma homocysteine concentration.
There was, however, no consistent evidence to show the effect of vitamin B 6 on lowering of fasting plasma homocysteine concentration. In the Physicians' Health Study, plasma pyridoxal 5 0 -phosphate (PLP) was inversely correlated with homocysteine (r ¼ À0.29, Po0.001) (Chasan-Taber et al, 1996) . In a recent randomized, double-blind, placebocontrolled trial, vitamin B 6 (1.6 mg/day) was given for 12 weeks to 11 healthy elderly subjects after repletion with folic acid and riboflavin. Results showed that vitamin B 6 supplementation significantly reduced fasting plasma homocysteine concentration by 7.5% (McKinley et al, 2001 ). In contrast, some studies showed that vitamin B 6 had no effect on fasting plasma homocysteine concentration. Miller et al (1992) indicated that total fasting plasma homocysteine concentrations were not initially elevated in vitamin B 6 -deficient humans and rats. Brattström et al (1990) studied homocysteine metabolism in 72 patients with occlusive arterial disease. The authors found that plasma PLP was decreased in most patients, but there was no correlation between plasma PLP and homocysteine concentration. In addition, 20 patients receiving pyridoxine hydrochloride (240 mg/day) alone for 2 weeks did not show a decrease in basal fasting plasma homocysteine concentration (Brattström et al, 1990) . In a placebo-controlled study, pyridoxine dose (10 mg) did not significantly reduce fasting plasma homocysteine concentrations (Ubbink et al, 1994) . A recent study reported that patients with cardiovascular disease had significantly lower plasma PLP than those of controls; however, fasting plasma homocysteine concentrations did not correlate with PLP levels (r ¼ À0.03, P40.05) (Chan et al, 2002) . It seems that the requirement for vitamin B 6 for lowering homocysteine needs further investigation.
Although the effect of vitamin B 6 supplementation on homocysteine is unclear at present, low vitamin B 6 status has been demonstrated to be an independent risk factor for cardiovascular disease (Serfontein et al, 1985; Robinson et al, 1995; Chan et al, 2002) . The present study was undertaken to ascertain whether various doses of vitamin B 6 supplementation would have beneficial effects on lowering fasting plasma homocysteine concentrations in CAD patients.
Methods
Patients A single-blind study was conducted from January 2002 to December 2002. Patients were recruited from the cardiology clinic of the Taichung Veteran General Hospital, which is a 1359-bed teaching hospital in the central part of Taiwan. The study patients were identified by cardiac catheterization to have at least 70% stenosis of one major coronary artery. All subjects with diabetes (defined by history of antidiabetic drugs use, or fasting plasma glucose concentration 4140 mg/ dl), liver, or renal diseases (identified by serum creatinine and aspartate aminotransferase analyses) were excluded to minimize the influence of other cardiovascular risk factors. Subjects currently taking vitamin-B supplements were also excluded. The use of medications was recorded. None of our subjects had acute myocardial infarction within the past 6 months. A total of 50 patients (46 men and four women) with the mean age of 71.679.7 y enrolled after informed consent was obtained. The study was approved by the Committee for Ethics of Chung Shan Medical University.
Experimental protocol
Patients were randomly assigned to one of five groups: placebo (n ¼ 10), 5 mg vitamin B 6 (pyridoxine HCl) (n ¼ 10), 10 mg vitamin B 6 (n ¼ 10), 50 mg vitamin B 6 (n ¼ 10), or 5 mg folic acid combined with 0.25 mg vitamin B 12 (hydroxycobalamin) (n ¼ 10). The vitamin tablets were commercially available preparations (Chin-Teng Pharmaceutical Industrial Co., Ltd, Taichung, Taiwan). Intervention was administered for 3 months. The patients were instructed to take one tablet daily after dinner or before going to bed and to refrain from using any other vitamin supplements during the study period. To monitor the compliance, investigators called every other week to remind patients to take the tablet. Patients returned to the cardiology clinic to get additional supplements, at which time any unused tablets from the previous 4 weeks were returned and counted. Subjects were taught to maintain their usual diets and activities during the study period. To ensure that patients were keeping their usual dietary intake, they completed 24-h diet recalls when they returned to the cardiology clinic before the intervention (week 0) and at week 12.
Fasting venous blood samples were collected in Vacutainer tubes (Becton Dickinson, Rutherford, NJ, USA) containing an EDTA as an anticoagulant to determine homocysteine and vitamin B 6 , and no anticoagulant to determine serum glucose, serum creatinine, total serum cholesterol, highdensity-lipoprotein cholesterol, low-density-lipoprotein cholesterol, triacylglycerol, alanine aminotransferase and serum alkaline phosphatase, vitamin B 12 , and folate status. During the intervention period, blood samples were taken on the fourth and 12th week after the subjects had fasted overnight. Blood samples were transported on ice and separated into plasma (or serum) and red blood cells within 1 h by lowspeed centrifugation (2500 r.p.m., 15 min). Samples were then stored frozen (À801C) until analysis.
Biochemical measurements
Fasting plasma homocysteine was measured by using highperformance liquid chromatography (HPLC) according to the method of Araki and Sako (1987) . The intra-and interassay of fasting plasma homocysteine variabilities were 5.1% (n ¼ 5) and 1.2% (n ¼ 8), respectively. Plasma PLP was determined by HPLC as previously described . The intra-and interassay of plasma PLP variabilities were 2.0% (n ¼ 6) and 2.9% (n ¼ 3), respectively. Erythrocyte alanine aminotransaminase (EALT) and erythrocyte aspartate aminotransaminase (EAST) with and without PLP stimulation in vitro were measured by the method of Woodring and Storvick (1970) . All EALT and EAST activity measurements were performed by using fresh erythrocyte samples collected on the day of analysis. The intra-and interassay of EALT and EAST activity coefficient (EALT-AC and EAST-AC) variabilities were 1.9% (n ¼ 5), 5.2% (n ¼ 14) and 2.0% (n ¼ 5), 4.1% (n ¼ 14), respectively. Plasma homocysteine and PLP concentrations and transaminase activity measurements were carried out under yellow light to prevent photodestruction. Serum folate and vitamin B 12 were analyzed by using standard competitive immunochemiluminometric methods on a Chiron Diagnostics ACS:180 Automated Chemiluminescence System (Chiron Diagnostics Corporation, USA). All analyses were performed in duplicate.
Statistical analyses
Data were analyzed using the SAS software package (version 6.12; The SAS Institute Inc., Cary, NC, USA). The KruskalWallis one-way analysis of variance on ranks was used to compare the differences in age, BMI, and hematological measurements among groups at baseline. Within each group, mean measurements of plasma concentration of homocysteine and PLP, serum folate and vitamin B 12 , and erythrocyte vitamin B 6 metabolites at weeks 4 and 12 were compared for significant differences with values at week 0 by using Friedman repeated measures analysis of variance on ranks. Pearson correlation coefficients were used to assess the relationship between fasting plasma homocysteine and Bvitamins. Statistical results were considered to be significant at Po0.05. Values presented in the text are means7standard deviation (s.d.) with the median value in parentheses.
Results
Characteristics of subjects Characteristics of subjects in each group are shown in Table 1 . A total of 42 CAD patients successfully completed the intervention study. Patients' ages ranged from 39 to 86 y, with a mean age of 71.4 y. There were no significant differences among groups with respect to age, BMI, and serum creatinine. The compliance of all was excellent.
Dietary intakes
Nutrient intake from the 24-h diet recall kept by the subjects at baseline and week 12 was calculated (data not shown). The mean intake of macronutrients, vitamin B 6 , folic acid, vitamin B 12 , and riboflavin between the baseline and week 12 was not significantly different in each group. In total, 90.5% and 64.3% of subjects had vitamin B 6 and folic acid intakes below the current Taiwan dietary reference intakes (Taiwan DRI; Department of Health, Taiwan, 2002) (vitamin B 6 : 1.6 mg/day; folic acid: 400 mg/day for both adult men and women 451 y), respectively. However, 69% of subjects, had mean vitamin B 12 intake higher than the current Taiwan DRI (2.4 mg/day for both adult men and women 451 y). No significant correlation was found between fasting plasma homocysteine and the intake of vitamin B 6 , folic acid, vitamin B 12 , or riboflavin (P40.05).
Vitamin-B intervention
At baseline (week 0), there were no significant differences with respect to fasting plasma homocysteine, plasma PLP, EALT-AC, EAST-AC, folic acid, and vitamin B-12 among the Vitamin B 6 had no effect on lowering plasma, homocysteine in CAD patients B-J Lee et al Vitamin B 6 had no effect on lowering plasma, homocysteine in CAD patients B-J Lee et al five groups. Baseline fasting plasma homocysteine concentrations ranged from 7.1 to 29.1 mmol/l, with a mean concentration of 14.4 mmol/l. The mean concentrations of plasma PLP, serum folic acid, and vitamin B 12 at baseline in each group were 420, 46.8 nmol/l, and 4125.0 pmol/l, respectively (Table 2) , which are the suggested values for adequate vitamin B 6 , folic acid, and vitamin B 12 status (Food and Nutrition BoardFInstitute of Medicine, 1998) . Table 2 shows responses of fasting plasma homocysteine and B-vitamins to 12-week supplementation with three different doses of vitamin B 6 or folic acid combined with vitamin B 12 in CAD patients. After 4 weeks of vitamin supplementation, supplementations of vitamin B 6 did not appear to affect fasting plasma homocysteine concentration when compared with the placebo treatment (P40.05). Similar results were found after 12-week supplementation of vitamin B 6 . The mean fasting plasma homocysteine concentration, however, significantly decreased after 12 weeks (P ¼ 0.047) of folic acid combined with vitamin B 12 supplementation when compared with mean concentration of the placebo-supplemented group.
A within-group comparison shows that only folic acid combined with vitamin B 12 supplement decreased fasting plasma homocysteine concentration significantly by 32.0% (Po0.001) after 12 weeks of vitamin supplementation when compared with the basal concentration (week 0) (Table 2) . However, 5 mg/day vitamin B 6 for 12-week supplementation only caused 2.1% nonsignificant reduction in fasting plasma homocysteine concentration (Table 2) . It was surprising to find that supplementations of placebo, 10 and 50 mg/day vitamin B 6 for 12 weeks slightly, although not significantly, increased the mean fasting plasma homocysteine concentration by 25.5, 16.2, and 18.3% in CAD patients, respectively (Table 2) .
Only in the group receiving the folic acid combined with vitamin B 12 did all patients respond with a reduction in fasting plasma homocysteine concentrations. In the other groups, the response of fasting plasma homocysteine concentrations to the vitamin supplements was not consistent (data not shown).
Pearson correlation coefficients were performed to understand the relation between B-vitamins and fasting plasma homocysteine. The fasting plasma homocysteine concentration was strongly and inversely associated with serum folate (r ¼ À0.261, P ¼ 0.0034) and vitamin B 12 (r ¼ À0.261, P ¼ 0.0032). There was no significant association between fasting plasma homocysteine and plasma PLP, EALT-AC, and EAST-AC (P40.05).
Discussion
Our previous study (Lee et al, 2003) and others (Brattström et al, 1990; Genest et al, 1990) have shown that hyperhomocysteinemia is prevalent in patients having CAD. If the fasting plasma homocysteine concentration could be effectively reduced by vitamin supplementation, it might lessen the morbidity and/or mortality of CAD. Our results were in agreement with previous studies (Brattström et al, 1990; Miller et al, 1992; Ubbink et al, 1994) , showing that vitamin B 6 supplementation did not affect homocysteine concentration. In addition, an unexpected finding was that fasting homocysteine levels slightly, although not significantly, increased in the placebo group during the study. The increase in homocysteine levels in the placebo group was not clear. This was a single-blind study; therefore, the expectation from the subject could be eliminated. Potential causes might be due to the nature of the coronary event, stress, or medication uses.
Our results, however, showed that the homocysteinelowering effect (E32% reduction) is significant by supplementation with 5 mg folic acid combined with 250 mg vitamin B 12 for 12 weeks in CAD patients. McKinley et al (2001) indicated that low-dose vitamin B 6 (1.6 mg/day) for 12 weeks effectively reduced fasting plasma homocysteine concentration in healthy elderly subjects only when subjects were both folate and riboflavin replete. Studies (Ubbink et al, 1994; Verhoef et al, 1996; Brouwer et al, 1999) have shown that folate is a very powerful homocysteine-lowering agent. A possible explanation has been attributed to the role of Sadenosylmethionine in the regulation of homocysteine metabolism. S-adenosylmethionine (an activator for the enzyme cystathionine b-synthase) favors folate and vitamin B 12 -dependent homocysteine remethylation to methionine in the fasting state; vitamin B 6 deficiency does not affect Sadenosylmethionine Ubbink et al, 1996) . Homocysteine is only directed to the trans-sulfuration pathway when methionine is in excess. Brattström et al (1990) indicated that supplementation with 240 mg of vitamin B 6 for 2-week decreased the mean post methionine load increase in the homocysteine concentration by 26% (Po0.001) in 20 very early-onset vascular disease patients. Other studies also showed similar results with a pyridoxine supplement at a dose of 20-100 mg (Dudman et al, 1993; Ubbink et al, 1996) . Vitamin B 6 , therefore, mainly affects homocysteine only in the postprandial state.
Moreover, we observed that high doses of vitamin B 6 supplementation slightly, although not significantly, decreased serum folate concentration after 4 weeks of vitamin B 6 supplementation ( Table 2) . Since plasma folate concentrations fluctuate rapidly with recent changes in folate intakes, we assessed subjects' dietary intakes. Subjects' mean folate intake remained nonsignificantly changed during the intervention period. The decrease in folate status, thus, might be due to the vitamin B 6 supplementation. Ubbink et al (1996) indicated that plasma folate concentration significantly declined during 20 mg pyridoxine supplementation in both asthma patients and healthy controls. A similar finding was seen in the study of Mansoor et al (1999) , the mean serum folate concentration decreased 13% after 120 mg vitamin B 6 supplementation for 5 weeks in healthy subjects. In a recent study, Bosy-Westphal et al (2001) observed a 27% reduction (Po0.01) of plasma folate concentration after 25 mg of pyridoxine supplementation for 10 days in healthy subjects. However, the underlying mechanism of serum folate reduction by a high dose of vitamin B 6 remains unclear at present. Further study is warranted to study the inter-relationship between vitamin B 6 and folate status.
Although serum folate concentration declined after vitamin B 6 supplementation, fasting plasma homocysteine concentration remained significantly unchanged in some previous studies (Ubbink et al, 1996; Mansoor et al, 1999; Bosy-Westphal et al, 2001) . It may be possible that homocysteine is directed to the trans-sulfuration pathway when the homocysteine remethylation is impaired by low folate status due to a temporary (short period) vitamin B 6 supplementation. However, supplementation of vitamin B 6 without folate repletion for a prolonged period might have negative effects on fasting plasma homocysteine concentrations since S-adenosylmethionine prefers the folate and vitamin B 12 -dependent homocysteine remethylation pathway. Arnadottir et al (1993) found that fasting plasma homocysteine concentrations increased significantly after a high dose of pyridoxine treatment (300 mg) for 4 months in dialysis patients. In the present study, there was a slight increase in fasting plasma homocysteine concentration during 12 weeks of 10 and 50 mg vitamin B 6 supplementation in CAD patients. We, therefore, speculated that if the intervention period of vitamin B 6 supplementation lengthens, serum folate status might probably be compromised. In the current study, the decrease in serum folate concentration after vitamin B 6 supplementation might be a reason to increase fasting plasma homocysteine concentrations.
Most of the studies were conducted on the role of vitamin supplementation in lowering homocysteine in subjects without CAD, or in those with high homocysteine levels. Although the small number of subjects in each subgroup was the major limitation of this study, our results could provide more information regarding what has been known in CAD patients. In conclusion, our study demonstrates that vitamin B 6 supplementation alone is less effective than folic acid combined with vitamin B 12 in lowering plasma homocysteine concentrations in CAD patients. It is possible that vitamin B 6 supplementation for a prolonged period might impair serum folate status and further cause hyperhomocysteinemia.
